Avid Trader

$GANX My Group Loaded $1.50-$1.75 Some FREE GAME For Twitter I Like The Stock… For a While Now Take 10 Minutes to READ What The Company is Doing For Parkinson’s Disease… Truly Incredible IMO Do NOT Sleep on This

The association between LDL reduction and coronary heart disease (CHD) risk reduction is sizable and confirmed by - Prospective cohort studies - Mendelian randomization - RCTs There really is no room to deny it. You can't get clearer than this:

Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!

President Donald Trump at his rally in Suffern, NY yesterday: “Micron, boy, Micron is great…” Is this what the $MU whales were waiting for? 👀

IRAN SAYS IN 'FINAL STAGE' OF DRAFTING FRAMEWORK FOR DEAL WITH US

$LLY Trillion Dollar Patent 👀

Dan Ives believes there is an 80% chance that SpaceX merges with Tesla in 2027. $TSLA

too much option pressure

$LLY RETATRUTIDE SHOWS 30.3% AVERAGE WEIGHT LOSS IN PHASE 3 EXTENSION Retatrutide is Lilly’s investigational triple agonist targeting GIP, GLP-1 and glucagon receptors. In TRIUMPH-1, Lilly studied 2,339 adults with obesity or overweight and at least one weight-related condition, excluding diabetes. 80-week results: 12 mg: -70.3 lbs, or -28.3% 9 mg: -64.4 lbs, or -25.9% 4 mg: -47.2 lbs, or -19.0% Placebo: -5.5 lbs, or -2.2% In the 12 mg group, 45.3% of patients lost 30% or more of body weight. 65.3% reached a BMI below 30 after 80 weeks. In the 104-week extension, patients continuing 12 mg lost an average of 85.0 lbs, or 30.3%. Most common side effects were nausea, diarrhea, constipation and vomiting. Discontinuation due to adverse events: 4 mg: 4.1% 9 mg: 6.9% 12 mg: 11.3% Placebo: 4.9% Retatrutide is still investigational and only available in Lilly clinical trials.